Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.
Triple Negative Breast Cancer
DRUG: Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|DRUG: Gemcitabine combined with carboplatin plus placebo
progression-free survival (PFS), The interval from the date of randomization until the first date on which progression, or death due to any cause, 36 months
This is a multicenter, randomised, double-blind, placebo-controlled, phase 3 trial. The main purposes of this study are to examine the efficacy and safety of standard chemotherapy plus moxifloxacin or placebo as first-line treatment in patients with metastatic triple-negative breast cancer. This study is designed to recruit up to 228 subjects.